Is the price fair?
What PODD's price assumes
Insulet Corporation trades at 26.9× earnings against 33.4× for the median Medical Devices name, cheaper than its own group.
26.9
Trailing P/E · Medical Devices median 33.4 · cheaper than the typical name in its group
- Price / sales
- 5.08
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.9%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +113% a year over the last three.
Details›
- Price / book2026-Q1
- 11.3
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $294M
- Market capitalisation
- $10.1B
- 3-year revenue growth
- +28%
- 3-year free cash flow growth
- +113%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.